Lee Walter T, Akst Lee M, Adelstein David J, Saxton Jerrod P, Wood Benjamin G, Strome Marshall, Butler Robert S, Esclamado Ramon M
Head and Neck Institute, Cleveland Clinic Foundation, Ohio Desk A71, 9500 Euclid Ave., Cleveland, Ohio 44195, USA.
Head Neck. 2006 Sep;28(9):808-12. doi: 10.1002/hed.20427.
Concurrent chemoradiation therapy has been demonstrated to be effective as an organ-sparing treatment for select advanced head and neck squamous cell carcinoma (HNSCC). However, this treatment modality is not without side effects. One side effect is the formation of upper esophageal strictures. As concurrent chemoradiation treatment is used more frequently, it is important to identify risk factors associated with stricture formation.
A retrospective chart review of all patients who had undergone definitive concurrent chemoradiation treatment between 1989 and 2002 was performed. Exclusion criteria included death within 1 year or persistent/recurrent disease that required surgical salvage at the primary site. The outcome measure was stricture formation as determined by both objective findings (barium swallow or endoscopy) and the need for dilation after treatment.
Of the 222 patients in this cohort, there were enough data for 199 patients to assess for stricture formation. Strictures developed in a total of 41 patients (21%). Significant predictive factors were a twice-daily (BID) radiation fractionation (p = .007), female sex (p = .015), and a hypopharyngeal primary site (p = .01). Age and tumor extent were not significant factors in stricture formation (p = .15 and p = .23, respectively).
Symptomatic strictures occur in 21% of patients undergoing concurrent chemoradiation for HNSCC. Female sex, BID radiation fractionation, and a hypopharyngeal primary site are significant predictive factors for stricture formation.
同步放化疗已被证明是一种有效的保留器官的治疗方法,用于特定的晚期头颈部鳞状细胞癌(HNSCC)。然而,这种治疗方式并非没有副作用。其中一个副作用是上食管狭窄的形成。随着同步放化疗的使用越来越频繁,识别与狭窄形成相关的危险因素很重要。
对1989年至2002年间接受确定性同步放化疗的所有患者进行回顾性病历审查。排除标准包括1年内死亡或原发性部位需要手术挽救的持续性/复发性疾病。结局指标是根据客观检查结果(吞咽钡剂或内镜检查)以及治疗后是否需要扩张来确定狭窄形成情况。
该队列中的222例患者中,有199例患者有足够的数据来评估狭窄形成情况。共有41例患者(21%)出现狭窄。显著的预测因素是每日两次(BID)的放疗分割(p = 0.007)、女性(p = 0.015)以及下咽原发性部位(p = 0.01)。年龄和肿瘤范围不是狭窄形成的显著因素(分别为p = 0.15和p = 0.23)。
接受同步放化疗的HNSCC患者中有21%出现有症状的狭窄。女性、每日两次的放疗分割以及下咽原发性部位是狭窄形成的显著预测因素。